Loading
IMNN-001 is an experimental interleukin-12 DNA plasmid immunotherapy from Imunon, in phase 3 trials for advanced epithelial ovarian cancer, fallopian tube cancer and primary peritoneal cancer.
IMNN-001 (GEN-1) is an interleukin-12 DNA plasmid immunotherapy (TheraPlas lipopolymer) from Imunon. A plasmid encoding interleukin-12, formulated with a PEG-PEI-cholesterol lipopolymer and given into the abdomen (intraperitoneally) with chemotherapy. Its furthest stage is phase 3, for advanced epithelial ovarian cancer, fallopian tube cancer and primary peritoneal cancer. ClinicalTrials.gov registers it in 4 studies linked below. Phase 3 OVATION 3 (NCT06915025) recruiting (registry, 3 Nov 2026). Whether it works in people has not been established unless a trial below reports it.
A plasmid encoding interleukin-12, formulated with a PEG-PEI-cholesterol lipopolymer and given into the abdomen (intraperitoneally) with chemotherapy.
1.IMNN-001 binds its target.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"IMNN-001" OR ABSTRACT:"IMNN-001" OR TITLE:"GEN-1" OR ABSTRACT:"GEN-1") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about IMNN-001, not a curated reading list.
Shares Imunon and the tag pipeline.
Shares Ovarian cancer and the tag pipeline.
Shares Ovarian cancer and the tag pipeline.
Shares Ovarian cancer and the tag pipeline.
Shares Ovarian cancer and the tag pipeline.
Shares Ovarian cancer and the tag pipeline.
Shares Ovarian cancer and the tag pipeline.
Shares Ovarian cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/